Catalog No.
KDH02205
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD279 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Sintilimab in the sample competitively binds to the pre-coated protein with biotin-labeled Sintilimab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Sintilimab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Sintilimab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
234.38 - 15,000 ng/mL
Sensitivity
110.56 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
9782.6
|
2116.9
|
487.7
|
9776.8
|
2197.0
|
486.2
|
|
Standard deviation
|
690.0
|
92.0
|
16.6
|
575.5
|
120.0
|
37.3
|
|
CV (%)
|
7.1
|
4.3
|
3.4
|
5.9
|
5.5
|
7.7
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Alternative Names
IBI-308, , CAS: 2072873-06-2
Background
Sintilimab is a monoclonal antibody against programmed cell death protein 1 (PD-1). It could block the interaction between PD-1 and its ligands and help the anti-tumor effect of T-cells to recover. Sintilimab is developed by Innovent Biologics and Eli Lilly and Company and has been approved to treat relapsed or refractory classical Hodgkin lymphoma in patients who have undergone two or more lines of systemic chemotherapy by the National Medical Products Administration of China. Recently, sintilimab has been reported in plenty of literature and shows satisfying anti-tumor effect. Meanwhile, there are some reports showing its side effects. Overall, sintilimab has similar anti-tumor effects and a better safety profile compared to nivolumab and pembrolizumab in Hodgkin lymphoma, natural killer/T cell lymphoma and advanced non-small cell lung cancer. In this review, we aim to briefly describe the mechanisms, pharmacological characteristics, anti-tumor effects, predictive parameters of efficacy and side effects of sintilimab, providing valuable information of sintilimab for decision-making in the treatment of tumors in the future.
Severe immunotherapy-related thrombocytopenia in metastatic bone cancer: a multicenter retrospective case series highlighting early recognition and management., PMID:40496609
Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report., PMID:40496608
Research progress of sintilimab in the treatment of cancer (Review)., PMID:40486088
Combination therapy of TKIs and ICIs for the treatment of anaplastic thyroid carcinoma., PMID:40485736
Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report., PMID:40481624
Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis., PMID:40481442
Stevens-Johnson syndrome induced by Sintilimab: a case report and literature review., PMID:40475009
Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)., PMID:40475000
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study., PMID:40472923
Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer., PMID:40469279
Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study)., PMID:40467307
Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study., PMID:40462321
Tertiary lymphoid structures signature predicts prognosis and clinical benefits from adjuvant chemotherapy and PD-L1 blockade in colorectal adenocarcinoma., PMID:40440077
The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194
Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study., PMID:40415559
Neurological and Cardiac Adverse Events in Cervical Cancer Treatment: A Case of Postoperative Sintilimab-Induced Encephalitis and Myocarditis., PMID:40415286
Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report., PMID:40406249
Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab., PMID:40406139
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study., PMID:40404633
Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review., PMID:40388765
Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report., PMID:40385299
Sintilimab‑induced acute erosive hemorrhagic gastritis as an adverse reaction of third‑line therapy in a nasopharyngeal carcinoma patient: A case report., PMID:40370643
Use of sintilimab in primary adenosquamous carcinoma of the liver results in pathological complete response: a case report and literature review., PMID:40370460
Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials., PMID:40360867
Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study., PMID:40356893
Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report., PMID:40342412
Pathological complete response after monotherapy with immune checkpoint inhibitors for bifocal colon cancer in a patient with lynch syndrome and situs inversus totalis: a case report., PMID:40330463
Prognostic value of the triglyceride-glucose index in advanced gastric cancer: A call for further exploration., PMID:40309236
Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer., PMID:40308504
Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial., PMID:40302640
Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature., PMID:40290678
Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review., PMID:40271131
Esophageal squamous cell carcinoma with colonic and rectal metastases: a rare case report., PMID:40265024
Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis., PMID:40264761
The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study., PMID:40263352
Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial., PMID:40260253
Isolated Adrenocorticotropic Hormone Deficiency Associated with Sintilimab in the Treatment of Lung Adenocarcinoma: A Case Report and Literature Review., PMID:40257860
Combination Therapy of Transarterial Chemoembolization, Lenvatinib, and PD-1 Inhibitors Achieves Significant Tumor Response in Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report., PMID:40256770
Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report., PMID:40255433
Correction to "Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single-Arm Study"., PMID:40254725
Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study., PMID:40252090
Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial., PMID:40251674
Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis., PMID:40247711
Long-term survival after chemotherapy combined immunotherapy for recurrent mixed neuroendocrine-non-neuroendocrine neoplasms of the common bile duct., PMID:40244371
Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report., PMID:40235902
Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study., PMID:40230857
Immunotherapy-associated autoimmune hemolytic anemia induced by anti-PD-1 therapy in esophageal cancer: A case report and literature review., PMID:40228248
Case Report: Esophageal cancer under comprehensive treatment strategy-application and clinical outcome analysis of combined immunotherapy, targeted therapy, and low-dose radiotherapy., PMID:40224180
Recombinant human‑endostatin combined with sintilimab and chemotherapy in first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma., PMID:40182608
Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome., PMID:40176803
For research use only. Not for human or drug use.
